Genetics in medicine open · 2026
Genome sequencing reveals the prevalence of Fabry disease-causing variants in Japan: Evidence from the Tohoku Medical Megabank.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Susukita Kai, Nochioka Kotaro, Takase Masato, Yamamoto Saori, Kumada Kazuki, Suzuki Hideaki, Ohneda Kinuko, Noguchi Kenichi, Izumi Yoko, Ogishima Soichi, Nakaya Naoki, Eto Yoshikatsu, Hozawa Atsushi, Yasuda Satoshi
Аннотация
BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficient α-galactosidase A activity and characterized by multisystem involvement. Although considered rare, with reported prevalence ranging from 1 in 40,000 to 1 in 140,000, its true frequency in the general population remains uncertain. We aimed to determine the prevalence of FD-causing variants in a community-based cohort from the Tohoku Medical Megabank, Japan.
METHODS: Genome sequencing was performed in 68,615 individuals. Variant pathogenicity was classified according to American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines. Baseline demographics, serum α-galactosidase A (GLA) activity, plasma globotriaosylsphingosine, and self-reported health data were assessed.
RESULTS: Pathogenic GLA variants were identified in 4 individuals and a likely pathogenic variant in 1 individual (mean age 49.3 ± 15.9 years); all were female, corresponding to a prevalence of 1 in 13,723. All pathogenic variants were c.902G>A, associated with the cardiac phenotype, whereas the likely pathogenic variant was c.1076T>C. Mean plasma GLA activity was 5.64 ± 1.73 mmol/hr/mL in pathogenic variant carriers and 8.36 mmol/hr/mL in the likely pathogenic carrier. Plasma globotriaosylsphingosine levels were 3.7 ± 0.79 ng/mL and 0.96 ng/mL, respectively.
CONCLUSION: Population based genome sequencing data suggest a higher prevalence of FD-causing variants in Japan than previously reported, highlighting potential underdiagnosis of late-onset FD in women.
METHODS: Genome sequencing was performed in 68,615 individuals. Variant pathogenicity was classified according to American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines. Baseline demographics, serum α-galactosidase A (GLA) activity, plasma globotriaosylsphingosine, and self-reported health data were assessed.
RESULTS: Pathogenic GLA variants were identified in 4 individuals and a likely pathogenic variant in 1 individual (mean age 49.3 ± 15.9 years); all were female, corresponding to a prevalence of 1 in 13,723. All pathogenic variants were c.902G>A, associated with the cardiac phenotype, whereas the likely pathogenic variant was c.1076T>C. Mean plasma GLA activity was 5.64 ± 1.73 mmol/hr/mL in pathogenic variant carriers and 8.36 mmol/hr/mL in the likely pathogenic carrier. Plasma globotriaosylsphingosine levels were 3.7 ± 0.79 ng/mL and 0.96 ng/mL, respectively.
CONCLUSION: Population based genome sequencing data suggest a higher prevalence of FD-causing variants in Japan than previously reported, highlighting potential underdiagnosis of late-onset FD in women.